Uremia: Clinical Trials

13 completed. 13 Phase 2.

By phase and status

Phase	Trials	Status
Phase 2	13	Completed 13

Follow Uremia: new trials by email Literature Review of Uremia trials Research Report on Uremia

Trials (filtered) newest first · largest first

All 13 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study to Assess Safety, Efficacy, and Pharmacokinetics of INM004 in Pediatric Patients With STEC-HUS INM004, SoC - Diarrhea-Associated Hemolytic Uremic Syndrome, Pediatric Kidney Disease	Phase 2	Completed	Inmunova S.A.	57	2022-10-06	2023-08-21
Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients Eculizumab - Thrombotic Microangiopathies, Atypical Hemolytic Uremic Syndrome	Phase 2	Completed	Children's Hospital Medical Center, Cincinnati	23	2018-08-03	2023-09-21
Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies OMS721 - Thrombotic Microangiopathies	Phase 2	Completed	Omeros Corporation	58	2014-11-02	2024-08-28
L-Cysteine in Peritoneal Dialysis L-cysteine, Placebo - Uremia	Phase 2	Completed	Mario Negri Institute for Pharmacological Research	10	2014-02-01	2015-06-30
The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS) Eculizumab - Atypical Hemolytic Uremic Syndrome (aHUS)	Phase 2	Completed	Alexion Pharmaceuticals, Inc.	2	2012-05-16	2017-03-10
A Study in Participants With End-Stage Renal Disease LY2127399 - Kidney Failure, Chronic	Phase 2	Completed	Eli Lilly and Company	18	2011-04-01	2018-05-14
Clinical and Biochemical Effects of Multipass Hemodialysis Multipass hemodialysis - Uremia	Phase 2	Completed	Herlev Hospital	12	2011-03-01	2013-07-09
An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome Eculizumab - Atypical Hemolytic-Uremic Syndrome	Phase 2	Completed	Alexion Pharmaceuticals, Inc.	22	2010-09-01	2015-04-29
An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome Eculizumab - Atypical Hemolytic-Uremic Syndrome	Phase 2	Completed	Alexion Pharmaceuticals, Inc.	44	2010-07-01	2017-05-30
Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive aHUS eculizumab - Atypical Hemolytic Uremic Syndrome	Phase 2	Completed	Alexion Pharmaceuticals, Inc.	5	2009-07-01	2015-07-23
Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (aHUS) eculizumab - Atypical Hemolytic Uremic Syndrome	Phase 2	Completed	Alexion Pharmaceuticals, Inc.	15	2009-07-01	2015-07-23
Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUS Eculizumab - Atypical Hemolytic Uremic Syndrome	Phase 2	Completed	Alexion Pharmaceuticals, Inc.	16	2009-05-01	2015-07-23
Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUS Eculizumab - Atypical Hemolytic Uremic Syndrome	Phase 2	Completed	Alexion Pharmaceuticals, Inc.	1	2009-05-01	2015-07-23

Narrower conditions

Atypical Hemolytic Uremic Syndrome (9)  ·  Thrombotic Microangiopathies (2)  ·  Hemolytic-Uremic Syndrome (1)  ·  Inflammation (1)  ·  Kidney Failure, Chronic (1)  ·  Multiple Organ Failure (1)

Broader conditions

Female Urogenital Diseases (13)  ·  Female Urogenital Diseases and Pregnancy Complications (13)  ·  Kidney Diseases (13)  ·  Male Urogenital Diseases (13)  ·  Urogenital Diseases (13)  ·  Urologic Diseases (13)  ·  Anemia (10)  ·  Anemia, Hemolytic (10)  ·  Blood Platelet Disorders (10)  ·  Cytopenia (10)  ·  Hematologic Diseases (10)  ·  Hemic and Lymphatic Diseases (10)  ·  Thrombocytopenia (10)  ·  Hemolytic-Uremic Syndrome (9)

Interventions

eculizumab (8)  ·  Cysteine (1)  ·  Dialysis (1)  ·  Renal Dialysis (1)  ·  narsoplimab (1)  ·  tabalumab (1)

Sponsors

Alexion Pharmaceuticals, Inc. (7)  ·  Children's Hospital Medical Center, Cincinnati (1)  ·  Eli Lilly and Company (1)  ·  Herlev Hospital (1)  ·  Inmunova S.A. (1)  ·  Mario Negri Institute for Pharmacological Research (1)  ·  Omeros Corporation (1)

Countries

United States (7)  ·  France (6)  ·  Germany (6)  ·  Italy (6)  ·  United Kingdom (6)  ·  Belgium (3)  ·  Canada (3)  ·  Netherlands (3)  ·  Austria (2)  ·  Sweden (2)  ·  Argentina (1)  ·  Australia (1)  ·  Bulgaria (1)  ·  Denmark (1)  ·  Hong Kong (1)

Top investigators

Fernando Goldbaum, PhD (1)  ·  James G Heaf, MD DMSc (1)  ·  Sonata Jodele, MD (1)

Results publications

PMID 33783815, PMID 23738544, PMID 21877169, PMID 23136214, PMID 25833956, PMID 25896788, PMID 26780484, PMID 35439028, PMID 37946262, PMID 41757982

NIH funding

2014 (1)